Emergent BioSolutions (EBS) Misses Q4 EPS by 16c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.05 -1.59%
Revenue Growth %: +32.0%
Financial Fact:
Total other income (expense): -1.93M
Today's EPS Names:
CCEL, FEIM, PLG, More
Revenue Growth %: +32.0%
Financial Fact:
Total other income (expense): -1.93M
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of $1.57, $0.16 worse than the analyst estimate of $1.73. Revenue for the quarter came in at $360.4 million versus the consensus estimate of $357.41 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
- Raymond James Previews Charles Schwab Corp. (SCHW) Earnings: 'Elevated Trading Volumes Drives Trading Revenue Upside'
- Ategrity reports record Q2 results, names new CFO
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
